Predilife SA
ALPRE
Company Profile
Business description
Predilife SA develops solutions of predictive medicine combining proven medical techniques (genetic tests, medical imaging) and mathematical models using a large number of statistical data that could allow each individual to define his risk profile for the occurrence of a large number of serious diseases. The company markets its Mammorisk personalized breast cancer screening solution in Europe and the United States.
Contact
114 rue Edouard Vaillant Espace Maurice Tubiana
Villejuif
Paris94800
FRAT: +33 142114211
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
20
Stocks News & Analysis
stocks
AI stocks post big gains in Q3. These are the winners and losers
Alphabet and Teradyne post big gains, while Salesforce and Adobe were down in the quarter.
stocks
12 picks for an income portfolio - Q3 2025 update
Fifteen months in and passive income growth has exceeded my target.
stocks
ASX’s only dividend aristocrat reports
Cyclical headwinds persist but loan book and industrial property prop up earnings.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,280.00 | 38.90 | -0.42% |
| CAC 40 | 7,971.78 | 109.76 | -1.36% |
| DAX 40 | 24,378.29 | 0.51 | -0.00% |
| Dow JONES (US) | 46,694.97 | 63.31 | -0.14% |
| FTSE 100 | 9,479.14 | 12.11 | -0.13% |
| HKSE | 26,957.77 | 183.15 | -0.67% |
| NASDAQ | 22,941.67 | 161.16 | 0.71% |
| Nikkei 225 | 47,944.76 | 2,175.26 | 4.75% |
| NZX 50 Index | 13,478.57 | 10.67 | -0.08% |
| S&P 500 | 6,740.28 | 24.49 | 0.36% |
| S&P/ASX 200 | 8,981.40 | 34.80 | -0.39% |
| SSE Composite Index | 3,882.78 | 20.25 | 0.52% |